论文部分内容阅读
目的深入研究糖尿病肾病患者的治疗药物及效果。方法 80例糖尿病肾病患者,随机分成研究组与参照组,每组40例。研究组患者采用罗格列酮与厄贝沙坦治疗,参照组患者采用二甲双胍与氨氯地平治疗。记录并比较两组患者治疗前后微量尿蛋白、尿蛋白、血糖、血压等变化情况。结果治疗前,研究组微量尿蛋白为(229.7±208.4)mg/L、尿蛋白为(1.1±0.9)g/24 h;参照组分别为(226.3±231.7)mg/L、(1.2±1.0)g/24 h。治疗后,研究组微量尿蛋白为(126.9±108.3)mg/L、尿蛋白为(0.5±0.4)g/24 h;参照组分别为(158.4±129.6)mg/L、(0.7±0.6)g/24 h。治疗前两组微量尿蛋白、尿蛋白水平比较差异无统计学意义(P>0.05);治疗后两组患者微量尿蛋白、尿蛋白均下降,且研究组下降幅度大于参照组,差异具有统计学意义(P<0.05)。治疗前,两组患者血压、血糖水平比较差异无统计学意义(P>0.05);治疗后,两组患者血压、血糖均有所下降,且研究组下降幅度大于参照组,差异具有统计学意义(P<0.05)。结论罗格列酮与厄贝沙坦能将尿蛋白、血糖、血压等指标控制在正常范围内,有效缓解临床表现,提高预后效果,应推广使用。
Objective To study the therapeutic drugs and their effects in patients with diabetic nephropathy. Methods 80 patients with diabetic nephropathy were randomly divided into study group and reference group, 40 cases in each group. Patients in the study group were treated with rosiglitazone and irbesartan, and patients in the reference group were treated with metformin and amlodipine. Record and compare the two groups of patients before and after treatment of trace proteinuria, urine protein, blood glucose, blood pressure and other changes. Results Before treatment, the urinary protein in the study group was (229.7 ± 208.4) mg / L and the urine protein was (1.1 ± 0.9) g / 24 h in the study group and (226.3 ± 231.7) mg / g / 24 h. After treatment, the urinary protein in the study group was (126.9 ± 108.3) mg / L and the urinary protein was (0.5 ± 0.4) g / 24 h respectively; the reference group was (158.4 ± 129.6) mg / / 24 h. Before treatment, there was no significant difference in urinary protein and urinary protein between the two groups (P> 0.05). After treatment, the levels of urinary protein and urinary protein decreased in both groups, and the decrease in the study group was greater than that in the reference group Significance (P <0.05). Before treatment, there was no significant difference in blood pressure and blood glucose level between the two groups (P> 0.05). After treatment, the blood pressure and blood glucose of both groups decreased, and the decrease rate of the study group was greater than that of the reference group (P <0.05). Conclusion Rosiglitazone and irbesartan can control urinary protein, blood glucose, blood pressure and other indicators within the normal range, effectively alleviate clinical manifestations and improve prognosis, should be widely used.